MacroGenics, Inc. Files Paperwork for $60 Million IPO
Published: Sep 05, 2013
Rockville-based biotech MacroGenics Inc. filed paperwork Wednesday for a $60 million initial public offering, in what would be the second Washington-area life sciences IPO in recent months. MacroGenics, a clinical-stage biotech focused on oncology, said it would use the proceeds to fund clinical development for margetuximab (also known as MGAH22) — currently in mid-stage trials for metastatic breast cancer and gastroesophageal cancer — and a second product, MGA271. Both are monoclonal antibodies. The cash from the IPO would also go toward advancing MacroGenics' early-stage pipeline.
Help employers find you! Check out all the jobs and post your resume.